Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Benfield

Showing results (281-290 of 293) with videos related to

Pageof 30
Sort By:
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis planM W Munch, Anders Granholm, S N Myatra, et al.
The New England Journal of Medicine|May 24, 2020
Remdesivir for the Treatment of Covid-19 - Final ReportJohn H Beigel, Kay M Tomashek, Lori E Dodd, et al.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
ESC Heart Failure|October 22, 2020
Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 studyMats Christian Højbjerg Lassen, Kristoffer Grundtvig Skaarup, Jannie Nørgaard Lind, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
The New England Journal of Medicine|December 28, 2020
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, Jens D Lundgren, Birgit Grund, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
Nature Communications|May 17, 2019
Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitisJohn A Lees, Bart Ferwerda, Philip H C Kremer, et al.
Annals of Internal Medicine|December 20, 2021
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial, Jens D Lundgren, Birgit Grund, et al.
Acta Anaesthesiologica Scandinavica|June 17, 2021
Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trialMarie Warrer Munch, Tine Sylvest Meyhoff, Marie Helleberg, et al.
Pageof 30

Showing results (281-290 of 293) with videos related to

Sort By:
Pageof 30
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis planM W Munch, Anders Granholm, S N Myatra, et al.
The New England Journal of Medicine|May 24, 2020
Remdesivir for the Treatment of Covid-19 - Final ReportJohn H Beigel, Kay M Tomashek, Lori E Dodd, et al.
Intensive Care Medicine|November 10, 2021
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trialAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
ESC Heart Failure|October 22, 2020
Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 studyMats Christian Højbjerg Lassen, Kristoffer Grundtvig Skaarup, Jannie Nørgaard Lind, et al.
Acta Anaesthesiologica Scandinavica|February 14, 2021
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysisAnders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, et al.
The New England Journal of Medicine|December 28, 2020
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, Jens D Lundgren, Birgit Grund, et al.
Intensive Care Medicine|April 1, 2022
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemiaAnders Granholm, Maj-Brit Nørregaard Kjær, Marie Warrer Munch, et al.
Nature Communications|May 17, 2019
Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitisJohn A Lees, Bart Ferwerda, Philip H C Kremer, et al.
Annals of Internal Medicine|December 20, 2021
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial, Jens D Lundgren, Birgit Grund, et al.
Acta Anaesthesiologica Scandinavica|June 17, 2021
Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trialMarie Warrer Munch, Tine Sylvest Meyhoff, Marie Helleberg, et al.
Pageof 30